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Abstract
Topical application of platelet-derived growth factor-BB (PDGF-BB) is considered to accelerate tissue repair of impaired
chronic wounds. However, the vast literature is plagued with conflicting reports of its efficacy in animal models and this is
often influenced by a wide array of experimental variables making it difficult to compare the results across the studies. To
mitigate the confounding variables that influence the efficacy of topically applied PDGF-BB, we used a controlled full
thickness splinted excisional wound model in db/db mice (type 2 diabetic mouse model) for our investigations. A carefully-
defined silicone-splinted wound model, with reduced wound contraction, controlled splint and bandage maintenance,
allowing for healing primarily by reepithelialization was employed. Two splinted 8 mm dorsal full thickness wounds were
made in db/db mice. Wounds were topically treated once daily with either 3 mg PDGF-BB in 30 ml of 5% PEG-PBS vehicle or
an equal volume of vehicle for 10 days. Body weights, wound contraction, wound closure, reepithelialization, collagen
content, and wound bed inflammation were evaluated clinically and histopathologically. The bioactivity of PDGF-BB was
confirmed by in vitro proliferation assay. PDGF-BB, although bioactive in vitro, failed to accelerate wound healing in vivo in
the db/db mice using the splinted wound model. Considering that the predominant mechanism of wound healing in
humans is by re-epeithelialization, the most appropriate model for evaluating therapeutics is one that uses splints to
prevent excessive wound contraction. Here, we report that PDGF-BB does not promote wound closure by re-
epithelialization in a murine splinted wound model. Our results highlight that the effects of cytoactive factors reported
in vivo ought to be carefully interpreted with critical consideration of the wound model used.
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Introduction
Wound healing is a complex process involving coordinated
interaction between cells and the extracellular matrix (ECM)
mediated by cytokines and various growth factors [1–3]. These are
harmonized by simultaneous and sequential events involving
hemostasis, inflammation, cell proliferation/migration, ECM
production, fibroplasia and wound contraction. Of the multiple
factors that affect wound healing, the role of growth factors has
been extensively studied, as they play a vital role in the regulation
of cell behaviors, and elaboration and remodeling of the ECM [3].
In vitro, various growth factors (EGF [4], VEGF [5,6], IGF [7],
NGF [8,9], PDGF [10–12]) have been demonstrated to stimulate
cell proliferation, migration, and synthesis and degradation of
extracellular matrix [13,14]. In vivo, when applied exogenously,
these factors may also promote wound healing [15–20]. Of the
numerous cytoactive factors investigated, platelet-derived growth
factor (PDGF) is the only recombinant cytokine growth factor
approved by the U.S. Food and Drug Administration to promote
wound closure via topical application [14]. Effects of PDGF-BB
topical application to accelerate tissue repair under conditions of
impaired wound healing have been demonstrated in animal
models [21,22] and human patients [23]. Currently, PDGF-BB
serves as the prototypical topical growth factor to facilitate chronic
wound healing [14,22]. However, conflicting reports detailing the
efficacy of PDGF exist within the vast wound healing literature
[22,24–27]. Especially, the models and relevant controls used in
those investigations widely vary, thus making it difficult to
compare the results across the studies.
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Diabetes mellitus is a chronic disease that leads to impaired
healing resulting in chronic wounds, for which treatment and
related complications are estimated to cost $10 billion annually.
The pathophysiology of diabetic wound healing and development
of new agents to improve clinical outcomes are continuously being
investigated. In order to understand the mechanisms involved in
impaired diabetic wound healing, and to test the efficacy and
safety of new therapeutic agents, many animal models have been
established and utilized. In particular, murine wound models have
many advantages such as relatively low cost, ease of housing and
handling that in turn support larger ‘n’ studies to increase
statistical power. Excisional wound models in type 2 diabetic (db/
db) mice have been widely utilized for investigations of impaired
wound healing including evaluating the efficacy of topical PDGF-
BB applied as a single agent or in combination with other
cytoactive factors [22,24–27]. However, the studies of PDGF-BB
on wound healing in db/db mice have resulted in inconsistent
findings depending on experimental variables such as wound size,
study end point, PDGF dosage, and delivery vehicle [22,24,26,27].
In some reports, PDGF treatment groups, in comparison to
control groups, had a decreased wound closure time or smaller
final wound size [22,24,25], while findings from other studies
suggest only an increase in granulation tissue and no significant
effect on the rate of wound closure [26,27].
Skin contracture is the primary mechanism of wound closure in
rodents; therefore the appropriateness of using mice for wound
healing studies has been debated [28,29]. This is particularly
important considering that re-epithelialization is an early and
critical event during the wound healing process in humans [28–
31]. To address this concern, the use of silicone splints to inhibit
dermal contraction has been promoted to increase the relevancy of
the murine model to wound healing in humans [30], and this
model was thus selected and modified for our studies. Using the
splinted wound model, it has been demonstrated that vascular
endothelial growth factor accelerated wound healing in db/db
mice [32].
Considering the negative to modest effect of PDGF-BB in
in vivo wound healing literature as well as the black-box warning
for incidence of tumors with prolonged application of 0.01%
PDGF-BB which is the currently used in clinics, an urgent need
exists to determine the appropriate clinical indication for which a
cytoactive factor is used in, and corresponding animal model to
test the efficacy of that cytoactive factor in chronic wound healing
and in diabetic wound management. To our knowledge, however,
the effect of PDGF-BB on re-epithelialization or wound closure of
splinted wounds in db/db mice has not been previously published.
Motivated by the conflicting results in the literature regarding the
efficacy of PDGF-BB in non-splinted murine wounds, the
increasing popularity of splinted wound models in assessment of
therapeutic effect, and the widespread clinical use of PDGF, the
study reported herein was undertaken. In this manuscript, we
report a controlled approach to monitor re-epithelialization and
test the efficacy of PDGF-BB in accelerating wound healing in
diabetic mice. The purpose of this study was to evaluate the effect
of PDGF BB on wound healing by re-epithelialization and
granulation tissue formation in db/db mice using a splinted wound
model. We anticipate that these data will serve as critical reference
for future studies investigating various drug delivery approaches
for increased cytoactive factor retention.
Materials and Methods
Ethics statement
All procedures adhered to the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol for this study was approved by
the Institutional Animal Care and Use Committee of the
University of California, Davis (Protocol number: 17294). All
surgery was performed under isoflurane anesthesia, and all efforts
were made to minimize suffering.
Cell culture and proliferation assay
Cell culture. Spontaneously immortalized non-tumorigenic
human keratinocyte cells (HaCaTs), generously provided by N.E.
Fusenig and P. Boukamp and also catalogued with the American
Type Culture Collection (ATCC; Manassas, VA), were used for
this study [33]. Primary human foreskin fibroblasts or HaCaTs
were routinely cultured in Ham’s F12 or DMEM medium
respectively supplemented with 10% (v/v) fetal bovine serum
(FBS), 1% (v/v) penicillin-streptomycin as described previously
[34,35]. Primary cells within passages 3–5 and HaCaT cells
between passages 20–30 were employed for all proliferation
experiments.
Proliferation assay. Human recombinant PDGF-BB (She-
nandoah Biotechnology Inc., USA) was dissolved in phosphate
buffered saline (PBS, pH 7.4) to obtain a stock solution of 100 mg/
ml. This was serially diluted in serum free growth medium to
obtain working concentration of 0, 7.5, 10, 50 ng/ml and 7.5 mg/
ml. Cells (7000/well) were seeded in a 48 well plate in growth
medium containing 1%(v/v) FBS and 1% (v/v) penicillin-
streptomycin, and then treated with the various concentrations
of PDGF-BB. Cell proliferation was measured after 5 days using
the widely reported MTT assay [36].
Receptor blocking proliferation assay. Prior to seeding,
cells were incubated with 10 mg/ml of goat polyclonal anti-PDGF
receptor beta antibody for 30 min at 37uC on an orbital shaker.
Cells were centrifuged at 1400 rpm for 5 min, the supernatant
discarded and the pellet resuspended in growth medium and then
plated in the presence of soluble of PDGF-BB as described above.
Proliferation was determined after 5 days using the MTT assay.
Animals
Twenty-four genetically diabetic 16 week old male mice (db/db;
BKS.Cg-m +/+ Leprdb; Jackson Laboratories, Bar Harbor, ME)
were used for this study. The average 6 SEM body weight of the
mice was 52.660.4 g. Mice were housed four animals per cage
pre-surgery and alone post-surgery; they were maintained in an
animal care facility with a 12 hour light/dark cycle for four weeks
prior to surgery and thereafter. Mice were randomly assigned to
one of two treatment groups: 30 ml of 0.01% (w/v) PDGF-BB in
vehicle (PDGF group; n = 12) and 30 ml of vehicle control [5% (w/
v) poly(ethylene) glycol (VEHICLE) group; n = 12]. The animal
number was calculated with power and sample size analysis based
on our previous study results. Alpha and beta levels were set at
0.05 and 0.8, respectively.
Anesthetic and Surgical Procedure
Anesthesia was induced and maintained with 2.25–2.50%
isoflurane in 100% oxygen, flow rate of 1.5–2 L/minute, using a
multi circuit anesthesia system for rodents (SAA2-3, Viking
medical, Minneapolis, MN). Buprenorphine HCl (0.05 mg/kg,
Buprenorphine HCl Injection, Ben Venue, OH) and lactated
ringer’s solution (10 mg/kg, Lactated ringer’s injection USP,
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Baxter, Deerfield, IL) were administered subcutaneously following
induction.
The mouse was positioned in ventral recumbency on a
temperature controlled heating platform (ACT 100, World
precision instruments, Sarasota, FL). The dorsal surface was
shaved with an electric clipper, sterilely prepped with 4%
chlorhexidine and 70% alcohol gauze sponges, and then sterilely
draped. All wounding procedures and post-operative treatments
were performed by one surgeon. Prior to wounding, two sterile
donut shaped splints (inner diameter of 10 mm, outer diameter of
14 mm) fabricated from 1.6 mm thick silicone sheet (Press-to-Seal
Silicone Sheet JTR-S-2.0, Grace Bio-Labs, Bend, OR) were
placed bilaterally around the pre-marked designated wound
location (the center of the wounds were located 40 mm cranial
from the tail head), and then adhered with an immediate-bonding
cyanoacrylate adhesive (Krazy Glue, Elmer’s product, Inc.,
Columbus, OH) and eight interrupted sutures using 6-0 nylon
sutures (6-0 Ethilon Nylon Suture, Ethicon LLC., Cornelia, GA).
A full thickness wound was created inside each splint by using an
8 mm sterile skin biopsy punch and a Westcott scissor. A trimmed
sterile plastic cover slip (Fischer Scientific, Pittsburgh, PA) was
placed on top of the splint, and a semi-occlusive dressing
(Tegaderm Film 9506 W, 3 M Health Care, St. Paul, MN) was
applied circumferentially around the trunk of the animal. Animals
were placed under a warming lamp and observed until they
recovered fully from anesthesia.
Clinical Evaluations and Treatments
Body weight, appetite, symptoms for pain (depression, agitation,
self-mutilating, and shivering), and general health condition were
monitored daily, and additional pain medication (buprenorphine
HCl, 0.05 mg/kg sc) was administered as needed. Mice were
briefly anesthetized with isoflurane for about 5 minutes daily
during bandage replacement, wound bed assessment, imaging,
and treatment. The semi-occlusive dressing was cut open daily,
along the coverslips placed on top of the splints, and the wound
bed was evaluated for splint stability, inflammation, or infectious
exudates. If excessive fluid accumulation was found, the fluid was
gently wicked away with a cotton tip applicator. Wound beds were
photographed on days 0, 2, 4, 6, 8, 10, and 11, with standardized
exposure and focal length using a digital camera with macro lens
and ring flash (Nikon D300, Nikon, Melville, NY) mounted on our
custom-made imaging station that provided incorporation of a
‘mm’ scale bar in each image obtained. Mice in the PDGF group
received 30 ml of 0.01% PDGF-BB (i.e. 3 mg dosage, PDGF-BB
Human Recombinant, Prospec, Ness-Ziona, Israel) dissolved in
vehicle, filter-sterilized 5% PEG (P156-500 Carbowax PEG 8000,
Fisher Scientific, Santa Clara, CA) in phosphate-buffered solution,
while the vehicle control group received 30 ml of the PEG vehicle.
Both wound beds in each animal were treated identically
immediately after surgery and once daily for 10 days. Following
evaluations and treatments, new sterile coverslips were placed over
the splints and a piece of Tegaderm dressing (Tegaderm Film
9506 W, 3 M Health Care, St. Paul, MN) was applied circumfer-
entially around the trunk of the mice. Bandages were replaced on
days 2, 5, and 8. All mice were euthanatized with an
intraperitoneal injection of Pentobarbital plus phenytoin (0.3 ml;
Buthanasia-D Special, Schering-Plough Animal Health, Union,
NJ) on day 11 following blood glucose measurement using a
glucometer (AlphaTRAK Blood Glucose Monitoring System,
Abbot Laboratories, North Chicago, IL).
Image Analysis
Photographs were analyzed to calculate percentage wound
closure and percentage wound contraction using image analysis
software (ImageJ, National Institutes of Health, Bethesda, MD,
USA) by a masked investigator. The outer and inner edges of
wound closure (Fig. 1) were traced. The area between these edges
the inwardly advancing newly epithelialized skin. Percentage
wound closure at each time point was calculated as (Fig. 1):
% Wound Closure= (Wound Area on Day 0– Area of Inner
Circumference on Day X)/Wound area on Day 06100.
Percentage wound contraction of each time point was calculated
as:
%Wound Contraction= (Wound Area on Day 0– Area of Outer
Circumference on Day X)/Wound Area on Day 06100.
Note, the area of inner circumference excludes reepithilializa-
tion, while the area of outer circumference includes reepithelial-
ization (see Fig. 1).
Histopathological Analysis
All histopathological analysis was performed by a board
certified veterinary pathologist who was unaware of experimental
group for each sample. Following euthanasia, the entire wound
and unwounded skin margins greater than 5 mm were excised to
the depth of the retro-peritoneum. Samples were fixed in formalin
for at least 24 hours and then sectioned through the center of the
lesion to obtain the largest diameter of the wound. Tissue samples
then underwent routine paraffin processing, were serially sectioned
at a thickness of 5 mm and stained with hematoxylin and eosin,
and picrosirius red. The widest section obtained was measured.
The sections were photographed using a mounted digital camera
(Olympus DP72, Melville, NY) and images were analyzed using
image analysis software (CellSence Dimension 1.4, Olympus,
Melville, NY) for length of reepithelialization, epithelial gap,
Figure 1. Photographs of a wound on Day 6 in a db/db mouse
treated with PDGF-BB. Area wound closure was calculated as
original wound area on Day 0– open wound area on Day ‘X’ (area inside
inner circumference indicated by a red line). Area wound contraction
was calculated as original wound area on Day 0– area including open
wound and new epithelium on Day ‘X’ (area inside outer circumference
indicated by a blue line).
doi:10.1371/journal.pone.0104447.g001
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amount of fibrovascular proliferation (granulation tissue) in the
dermis, and inflammatory response.
Length of reepithelialization was defined as the length of the
layer of proliferating keratinocytes covering the wound area. This
value was obtained by measuring the distance between the free
edge of the keratinocyte layer and the base where the cells were
still associated with native, non-affected dermal tissue (Fig. 2A).
Both sides of the lesion were measured and the final result was the
sum of the two measurements. For wounds that had been
completely re-epithelialized, a single measurement was taken from
dermal edge to dermal edge. The epithelial gap was defined as the
distance between the advancing edges of keratinocyte migration
(Fig. 2A). Fibrovascular dermal proliferation (granulation tissue)
was measured by examining the Picrosirius red-stained sections
under polarized light which highlighted the newly deposited
dermal collagen. Using the image analysis software the wound bed
area was selected and the amount of collagen deposition in the
selected area was automatically measured and was expressed as a
percentage of the wound area (Fig. 2C, D and E). The
inflammatory response was assessed using a semi-quantitative
scoring system ranging from 0 to 4 where 0 indicates no
inflammation, 1 indicates that 0–25% of the wound area was
infiltrated by inflammatory cells, 2 indicates 25–50%, 3 indicates
50–75%, and 4.75% of the wound area was infiltrated.
In our study, instead of subjectively estimating the area of
apparent granulation tissue formation in the wound bed, we
determined the collagen content in the whole wound by a semi-
quantitative method. Preliminary studies verifying the validity of
this approach demonstrated a correlation between a simple
measurement of the area of peripheral granulation tissue with
the quantitated collagen content. In our study collagen content in
the wound bed was measured by quantifying the amount of
Picrosirius red stained tissues under polarized light microscopy and
using automated imaging analysis. We accurately determined the
early fibroblastic reaction infiltrating the center of the wound in
addition to the dense and well-formed granulation tissue at the
edges of the wound bed. We believe that this method provides an
accurate representation of the fibrovascular reaction associated
with the healing process in the whole wound bed, especially in the
diabetic mice where infiltration of fibrovascular tissue between the
adipocytes is a feature [37].
Exclusion Criteria
Exclusion criteria included wound infection, spontaneous death,
tissue destruction during processing for histopathological exami-
nation, and splint failure. Splint failure was defined as one or more
of the following: splint fracture; partial or complete detachment of
splint; two or more sutures missing or released. When one missed
or released suture was found during daily examination, the suture
was restored.
Statistical Analysis
Results are expressed as mean 6 SEM. Data from individual
mouse bilateral wounds were averaged and considered as one data
point. If one of the two wounds were excluded during the
experiment based on exclusionary criteria, data from only the
inclusionary wound was used as the data point for comparisons.
Statistical analysis was performed using a commercially available
statistical software SPSS (version 15.0, SPSS Inc, Chicago, IL). For
Figure 2. Histopathological evaluations of a wound bed from a db/db mouse treated with PDGF-BB for 10 days and harvested 11
days after wounding. Scale Bars = 500 mm. (A) Measurement of epithelial gap (dotted black line) and reepithelialization (dotted red lines). The
epithelial gap was defined as the distance between the advancing edges of keratinocyte migration measured in millimeters. Length of
reepithelialization was defined as the length of the layer of proliferating keratinocytes covering the wound area. This value was obtained by
measuring s the distance between the free edge of the keratinocyte layer and the base where the cells were still associated with native, non-affected
dermal tissue (*). The black vertical lines denote the area of separation between the pre-existing collagen and wound bed. The final value was the
sum of distance in millimeters of both sides. H&E staining. (B) Inflammatory infiltrate in the wound bed. The inflammatory response was assessed
using a semi-quantitative scoring system ranging from 0 to 4 where 0 indicates no inflammation, 1 indicates 0–25% of the wound area affected, 2
indicates 25–50% of the wound area affected, 3 indicates 50–75% of the wound area affected, and 4 indicates.75% of the wound area affected. This
sample was classified as score 2. H&E staining. (C, D and E) Measurement of the fibrovascular dermal proliferation in the wound bed. Picrosirius red
staining. (C) The wound bed area is outlined (green lines), comprising a preset depth of 0.75 mm (this is the average depth of the wounds in the
experiment) and the borders between preexisting dermal collagen and newly formed collagen. (D) Under polarized light the bright collagen fibers of
the wound bed are highlighted and automatically measured by the software (E), and the final data is expressed as a percentage of outlined wound
area.
doi:10.1371/journal.pone.0104447.g002
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the in vitro proliferation assay, statistical significance was deter-
mined by one-way analysis of variance (ANOVA) followed by
Dunnett’s multiple comparison test. The effects of mouse strain,
presence of the splint, dressing, treatment, time, and interaction
between time and each effect on the body weight, wound healing,
and contraction were evaluated using repeated measures AN-
OVA. Histological scores were compared between the groups by
using the Student’s t-test. Values of P,0.05 were considered
significant.
Results
PDGF-BB stimulates cell proliferation in vitro
Proliferation was significantly higher in PDGF-BB treated
fibroblasts (all doses) compared to untreated cells. The dose
response was trimodal in nature. Maximum proliferation was
observed for the following doses: 7.5 ng/ml, 50 ng/ml and
7.5 mg/ml (Fig. 3A). Proliferation in treated cells, while remain-
ing higher than in untreated cells, appeared to decrease between
7.5 ng/ml to 15 ng/ml before again increasing. When the cells
were blocked with an antibody to the PDGF beta receptor,
proliferation was significantly reduced for all concentrations,
approximating results obtained for untreated cells (Fig. 3B).
HaCaT cells treated with PDGF-BB did not show any demon-
strable significance in proliferation rates (data not shown).
PDGF-BB does not promote closure of splinted wounds
in db/db mice
Unilateral wound from 8 mice (5 controls and 3 treated) were
excluded from the study based on our strict exclusion criteria.
However we were able to use data obtained from the contra-lateral
wounds, therefore all animals (24/24) were included for data
analysis. Mean 6 SEM percentage wound closure on day 11 was
86.166.2% in the PDGF group and 89.765.3% in the vehicle
group (Fig. 4A). Mean 6 SEM percentage wound contraction
was 22.661.9% in the PDGF group, and 22.064.7% in the
vehicle group (Fig. 4B). In overall comparisons, no significant
effect of treatment on wound contraction or closure between the
PDGF and VEHICLE groups was observed (Fig. 4 A, B). In
histopathological evaluations, there were no significant differences
in epithelial gap (P = 0.74) or reepithelialization (P = 0.47) (Fig. 4
C, D). There were also no significant differences in collagen
content (P = 0.62) or inflammation score (P = 1.00, Fig. 5)
between groups.
Discussion
In this study, the applicability of a splinted wound model to
ascertain the ability of PDGF-BB in facilitating wound closure was
evaluated. The results of this study would become baseline data for
using the splinted wound model to evaluate advanced technologies
developed to improve delivery of PDGF-BB for the treatment of
chronic wounds.
The bioactivity and specificity of PDGF-BB in facilitating cell
proliferation was determined using in vitro cell proliferation
assays. In vitro, PDGF-BB significantly accelerated cell prolifer-
ation in a trimodal pattern with maximum effects observed at
7.5 mg, 50 ng and 7.5 ng in this study (Fig. 3A). Blocking PDGF
receptor beta significantly inhibited the proliferative ability PDGF-
BB. In vivo, significantly accelerated wound closure was demon-
strated in previous studies [25,38,39] when PDGF-BB was applied
in the order of micrograms per wound. Based on these previous
studies and results from our in vitro studies and, a dose of 3 mg per
wound (8 mm diameter) was chosen for this study, which
corresponds to approximately 6 mg/cm2. Wounds were treated
daily for 10 days after wounding. Considering that the wounds in
our study were smaller (at least one fourth the wound area
compared to other studies) we chose to monitor wound closure
over 11 days after wounding instead of the 21 days for the larger
wounds previously reported [25,38,39].
Previously published reports have shown variability in efficacy
of PDGF-BB in promoting closure of nonsplinted wounds in db/
db mice depending on experimental conditions such as PDGF
dosage, treatment duration, and study endpoint [24–27,38,39].
Predominant experimental differences between previous studies
[24,25,39] and this one were (a) wound size, which for our study
was approximately four times smaller (based on total wound
surface area), and (b) duration of follow-up (11 days vs 21 days).
On gross image analysis, we observed that wounds in both groups
(PDGF-BB and vehicle control) had approximately 85–90%
closure 11 days after wounding. This endpoint is concurrent with
previous studies showing similar healing rates of 80.9, 88.2, and
90.6% in PDGF treated groups on day 21 [25,39]. Greenhalgh
et al [25], the first to report that PDGF-BB significantly enhanced
wound healing in full thickness wounds of db/db mice,
demonstrated that effective wound closure accompanied by
improved granulation tissue formation was observed 21 days after
wounding in a 15 mm615 mm square full thickness wound on the
back of mice treated with 10 mg per wound PDGF-BB (4.4 mg/
cm2 wound area) for 5 and 10 days. However, they did not observe
Figure 3. Soluble PDGF-BB promotes proliferation of primary
foreskin fibroblasts over 5 days, and can be attenuated by
blocking PDGF beta receptors. (A) A trimodal dose dependent
response was observed with peak proliferation at 7.5 ng/ml, 7.5 and
50 mg/ml. Results are Mean 6 StDev, n = 6. (B) Cell proliferation over 5
days was inhibited for all concentrations of PDGF-BB when PDGF-B
receptor in cells were blocked with 10 mg/ml of PDGF beta receptor
antibody for 30 min at 37uC prior to cell seeding. Results are Mean 6
StDev, n = 6. * P,0.05, *** P,0.001.
doi:10.1371/journal.pone.0104447.g003
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any differences in wound closure up to 10 days after wounding for
treated groups. Other studies [24,39,40] have monitored larger
wounds for up to 21 days after wounding and have demonstrated a
similar positive effect. Considering the differences in results
Figure 4. PDGF-BB did not accelerate wound closure, contraction or reepithelialization in the mouse splinted full thickness dermal
wound model. Percentage wound closure (A) and contraction (B) as mean 6 SEM in full thickness splinted wounds of db/db mice treated with
0.01% PDGF-BB or vehicle control. Wound area was measured from photographs taken immediately after wounding, and then the area including
open wound plus new epithelium was measured from photographs taken day 2, 4, 6, 8, 10, and 11. Percentage wound contraction and closure was
calculated as described in methods. Epithelial gap (C) and reepithelialization (D) were measured by histopathological evaluation. All data were
expressed as mean 6 SEM. No significant differences between groups were found in any comparision.
doi:10.1371/journal.pone.0104447.g004
Figure 5. PDGF-BB did not modulate collagen deposition and inflammation development at the wound site in the splinted full
thickness dermal wound model in mice. Percentage collagen content (A) and inflammation score (B) as mean 6 SEM in full thickness splinted
wounds of db/db mice treated with 0.01% PDGF-BB or vehicle control. No significant differences in percentage collagen content or inflammation
score were found (P.0.62).
doi:10.1371/journal.pone.0104447.g005
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between our study and others, it can be inferred, retrospectively,
that the size of a wound accompanied by the duration of follow-up
are critical parameters to consider while demonstrating any
potentially observable effects of PDGF-BB.
Another difference between previous studies [24,25,38,39] and
this study is that we placed a silicone splint around the wound to
reduce wound contraction. This is a critical difference when
considering the primary mode of wound healing in rodents (by
contraction) and humans (by reepithelialization). While Senter
et al. [26] hypothesized that the primary effect of PDGF-BB on
wound healing is by acceleration of contraction, other studies have
suggested that PDGF-BB facilitates wound healing in vivo by
chemotactic and mitogenic promotion of granulation tissue
formation and reepithelialization [25,39]. However, direct com-
parisons to these studies are not feasible due the variation between
species, models, treatment times, wound size etc. In order to
mitigate the number of unknowns, in this study, we investigated
the efficacy of PDGF-BB in facilitating wound closure by re-
epithelialization using a controlled, validated and well defined
splinted full thickness wound model. This model was developed to
minimize multiple confounding factors often affected by inconsis-
tent splint and bandage maintenance, and direct contact of
bandage to wound surfaces. Our data clearly demonstrate that
there are no differences observed in wound contraction or
epithelialization in splinted mouse wound model in the presence
or absence of PDGF-BB. To our knowledge there are no published
reports detailing the differences in PDGF-BB mediated wound
contraction observed between a splinted and unsplinted model.
Another factor that can impact wound closure is the dressing
methods. The importance of application and maintenance of semi-
occlusive dressings, and infection control have been discussed
previously [27]. A correlation between accumulation of exudate/
fluid and decreased reepithelialization in db/db mice has been
previously reported [26]. In our study, we placed a sterile coverslip
over the splint to prevent direct contact of adhesive dressing with
the wound bed; this was done to protect the wound bed and to
prevent any inadvertent effects on wound healing. Additionally,
excessive fluid was removed prior to treatment, and coverslips
were replaced daily in order to maintain a clean wound bed. It is
thus possible that by our dressing method and by maintaining a
clean wound bed, a better environment for healing was provided
for both control and PDGF groups.
The bioactivity of PDGF-BB used in the study as confirmed
in vitro using fibroblasts and keratinocytes. Our in vitro results
demonstrate that PDGF-BB did not accelerate proliferation of
HaCaTs, but effectively increased proliferation of primary human
foreskin fibroblasts. The failure to promote proliferation of
HaCaTs in response to PDGF-BB was anticipated as they
inherently lack PDGF beta receptors [41]. A prerequisite for
PDGF to promote wound healing is that the cells present in the
wound bed express PDGF receptors. In vivo the baseline
expression of PDGF receptors have been reported to be
significantly inhibited in genetically diabetic db/db mice; expres-
sion of the B-type receptor is further inhibited during repair [42].
Although we did not quantify the in vivo expression of PDGF
receptors in our study, we can relate our findings and infer from
previous studies that the expression of PDGF B receptors, required
for a PDGF-BB specific response, is significantly inhibited. This
may lead to inhibition of both the autocrine and paracrine
signaling effects of PDGF required for healing. We also recognize
that the expression and activities of matrix metalloproteinases and
other proteases are altered during diabetes and may contribute to
accelerated degradation of growth factors [43–46] present
inherently in the wound site or those topically administered. In
this study, we did not observe any impairment or acceleration in
wound closure by re-epithelialization in PDGF treated mice when
compared to control groups. While it is indeed possible that
proteases may have led to excessive proteolysis of PDGF-BB
administered, contrary to the recommended clinical usage of
PDGF-BB for treatment of diabetic foot ulcers, we did not observe
any change (impairment or acceleration) in wound healing (in db/
db mice) upon PDGF treatment using the splinted model.
Advanced protein glycosylation is a process of non-enzymatic
modification of proteins and plays a significant role in ageing and
diabetic pathology. Advanced glycation end products (AGE)
generated as a result of this process can exacerbate the disease
process via oxidative damage, apoptosis and inflammation, and is
implicated in Alzheimer’s disease, cardiovascular disease and
diabetes mellitus to name a few [47]. Indeed, AGE precursors can
impair or alter the post-translation modification of receptors of
growth factors thus modifying their biological activity. For
example, AGE precursors inhibit epidermal growth factor
receptor (EGFR) dephosphorylation, and promote EGFR cross-
linking thereby modifying EGF signaling [48]. Similarly, methyl-
glyoxal (an AGE precursor) can induce AGE formation resulting
in PDGF receptor b dysfunction [49]; also, glycation of PDGF
itself can also inhibit its biological activity and may thus impair
wound repair [50]. Consistent with these, we observed that
treatment of PDGF-BB did not have any significant effect on
wound healing. In this study, the extent to which AGE mediated
inhibition of PDGF receptor or glycation of exogenously added
PDGF-BB contributes to a lack of accelerated wound healing is
not known.
The results of this study demonstrated no detectable effect of
PDGF-BB on wound healing in db/db mice with splinted full
thickness wounds. A species specific difference in the usage of
human recombinant PDGF-BB to treat chronic wounds in mice is
highly unlikely considering that PDGF-BB is mitogenic in murine
cells [51,52]. These results are very important to take into account
while making a choice between PDGF-BB or other cytoactive
factors for treatment of chronic wounds; especially considering
that the use of PDGF-BB is associated with an FDA ‘black box’
warning for potential neoplastic growth. However, this study
clearly identifies multiple confounding variables within an animal
model while investigating the effects of cytoactive factors for
wound healing. In summary, the use of a splint for excisional
wounds is optimal to observe wound closure by reepithelialization.
Meticulous application, maintenance and monitoring of the
wound bed with minimal complications are possible with our
modified silicone splinted model. This study clearly demonstrates
that the effects of cytoactive factors reported in vivo needs to be
carefully interpreted with critical consideration of the wound
model used and there is much remaining to be understood about
the effect of growth factors for treatment of chronic wounds,
especially in disease models.
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